Welcome to our dedicated page for Aura Biosciences news (Ticker: AURA), a resource for investors and traders seeking the latest updates and insights on Aura Biosciences stock.
Aura Biosciences, Inc. (AURA) is a clinical-stage biotechnology company pioneering precision therapies that target solid tumors while preserving critical organ function. This page serves as the definitive source for investors and medical professionals tracking the company's progress in ocular oncology and bladder cancer treatments.
Access real-time updates on clinical trial developments, regulatory milestones, and strategic partnerships. Our curated news collection includes press releases covering drug candidate advancements (including lead program bel-sar), financial disclosures, and scientific presentations—all essential for evaluating AURA's position in targeted cancer therapeutics.
Key content categories include clinical trial phase updates, FDA designation announcements, collaborative research initiatives, and financial performance reports. The company's innovative molecular surgery approach—combining direct tumor targeting with immune activation—is reflected across all coverage.
Bookmark this page for streamlined monitoring of AURA's progress in vision-preserving ocular melanoma treatments and organ-sparing bladder cancer therapies. Check regularly for authoritative updates on this clinical-stage innovator's journey through the drug development pipeline.
Aura Biosciences (NASDAQ: AURA) announced FDA Fast Track Designation for belzupacap sarotalocan (bel-sar) to treat choroidal metastasis, signifying a significant opportunity for a new standard of care. Following positive Phase 2 results for early-stage choroidal melanoma, the global Phase 3 trial is set to begin dosing in 1H 2023. Financial results reveal a cash position of $188.8 million, sufficient to fund operations into 2025.
However, R&D expenses surged to $42.2 million, contributing to a net loss of $58.8 million for the year.
Aura Biosciences, Inc. (Nasdaq: AURA) announced positive interim Phase 2 safety and efficacy data for its treatment, bel-sar, aimed at early-stage choroidal melanoma. Results showed an impressive 100% tumor control rate and an 88% visual acuity preservation rate after an average of nine months follow-up in patients. The therapy demonstrated favorable safety, with only one case of visual acuity loss and no serious adverse events reported. Aura plans to initiate a global Phase 3 trial this year, bolstering confidence in bel-sar's potential as a first-line treatment. These results were presented at the Macula Society’s 46th Annual Meeting in Miami, FL.
FAQ
What is the current stock price of Aura Biosciences (AURA)?
What is the market cap of Aura Biosciences (AURA)?
